Elevation Oncology, Inc. (ELEV)
After hours:
| Previous close | 2.8900 |
| Open | 2.9300 |
| Bid | 2.9200 x 400 |
| Ask | 2.9500 x 400 |
| Day's range | 2.8662 - 3.0500 |
| 52-week range | 0.3630 - 5.8300 |
| Volume | |
| Avg. volume | 824,640 |
| Market cap | 160.09M |
| Beta (5Y monthly) | 1.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8500 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.17 |
PR NewswireElevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced plans to expand its ongoing Phase 1 clinical trial to include two combination cohorts evaluating EO-3021 for the treatment of advanced gastric or gastroesophageal junction cancer. Following recently signed clinical supply agreements with Eli Lilly and Co
- PR Newswire
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 11:30 am ET.
- PR Newswire
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and highlighted recent business achievements.
